University of Ioannina
Επίδραση των συνδυασμών βαλσαρτάνης/ αμλοδιπίνης ή ντελαπρίλης/μανιδιπίνης ή τελμισαρτάνης/αμλοδιπίνης στην αντίσταση στην ινσουλίνη σε υπερτασικούς ασθενείς με διαταραχή γλυκόζη νηστείας
Abstract
dc:descriptionBackground: The effect of antihypertensive drugs on glucose homeostasis and insulin resistance remains an issue under investigation. There is evidence that renin-angiotensin system (RAS) blockers may favorably affect glucose metabolism, while treatment with calcium channel blockers (CCBs) is considered to have an overall neutral metabolic effect. However, the effects on glycemic indices may differ among agents within the same class of antihypertensive drugs.Objective: To evaluate the effects of different fixed-dose single pill combinations of RAS blockers with CCBs on homeostatic model assessment for insulin resistance (HOMA-IR).Methods: Drug-naive patients with arterial hypertension (AH) and impaired fasting glucose (IFG) were randomly allocated to open-label fixed, single pill combinations of valsartan 160 mg/day plus amlodipine 5 mg/day (VAL/AMLO group, n = 54), delapril 30 mg/day and manidipine 10 mg/day (DEL/MANI group, n = 53) or telmisartan 80 mg/day and amlodipine 5 mg/day (TEL/AMLO group, n = 51) for 12 weeks. Glycemic indices and HOMA-IR were determined at baseline and post-treatment.Results: A total of 158 patients were included. All treatment combinations effectively reduced blood pressure (systolic and diastolic) to similar levels (all p < 0.001). A decrease in the HOMA-IR index by 22.55% (p < 0.01) was noted following treatment with TEL/AMLO, while an increase by 1.4% (p = 0.57) was observed in the VAL/AMLO group and by 12.65% (p = 0.072) in the DEL/MANI group. These changes were significantly different between TEL/AMLO and DEL/MANI (p < 0.05) as well as between TEL/AMLO and VAL/AMLO (p < 0.001). No statistically significant changes were observed in the lipid parameters for each treatment group. Only DEL/MANI treatment resulted in significant reductions in lipid parameters; total cholesterol and triglyceride levels. TEL/AMLO administration resulted in statistically significant reduction in γ-GT levels. Renal function was not adversely affected by any of the 3 treatment groups. TEL/AMLO treatment resulted in greater reductions in urine albumin levels per gram of urine creatinine (uMalb/uCr ratio) than the other groups. No significant changes in electrolyte levels were observed for all treatment groups. Regarding serum potassium levels, there was not observed any incidence of hyperkalemia (> 5 mEq/L) either at baseline visit or at the end of the study follow-up period (DEL/MANI: 4.34 vs 4.36, TEL/AMLO: 4.34 vs 4.48, VAL/AMLO: 4.3 vs 4.42 mEq/L, respectively). The primary goal of antihypertensive treatment (BP < 140/90 mmHg) according to the ESC 2013, 2018 and 2021 guidelines was achieved in approximately half of the patients (50.94%, n = 27) in the DEL/MANI group. In the other 2 treatment groups, less than half of patients (47.06%, n = 24 in the TEL/AMLO group and 37.04%, n = 20 in the VAL/AMLO group) achieved the primary BP goal. In contrast, the rate of achieving the more ambitious BP goal < 130/80 mmHg was even lower for all 3 treatment groups (5.66% for the DEL/MANI group, 5.88% for the TEL/AMLO group and 9.26% for the VAL/AMLO group).Conclusions: Despite similar antihypertensive action, the effect of fixed, single pill combinations with TEL/AMLO, VAL/AMLO and DEL/MANI on insulin resistance is in favor of TEL/AMLO.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Liontos, Angelos
- Λιόντος, Άγγελος
Subjects
dc:subject × 16- Αρτηριακή υπέρταση
- Διαταραχή ομοιοστασίας των υδατανθράκων
- Διαταραχή στη Γλυκόζη νηστείας
- Αντίσταση στην ινσουλίνη
- Arterial hypertension
- Carbohydrate homeostasis disorder
- Impaired fasting glucose
- Insulin resistance
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ενδοκρινολογία, Διαβήτης και Μεταβολισμός
- Γενική και Εσωτερική ιατρική
- Clinical Medicine
- Medical and Health Sciences
- Endocrinology, Diabetes and Metabolism
- General and Internal Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52835